Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
about
One-shot NMR analysis of microbial secretions identifies highly potent proteasome inhibitorOmuralide and vibralactone: differences in the proteasome- β-lactone-γ-lactam binding scaffold alter target preferencesSystematic comparison of peptidic proteasome inhibitors highlights the α-ketoamide electrophile as an auspicious reversible lead motifSelective inhibition of the immunoproteasome by ligand-induced crosslinking of the active siteIndolo-phakellins as β5-specific noncovalent proteasome inhibitorsA Minimal β-Lactone Fragment for Selective β5c or β5i Proteasome InhibitorsIdentification of a β1/β2-specific sulfonamide proteasome ligand by crystallographic screeningReversible Inhibitors Arrest ClpP in a Defined Conformational State that Can Be Revoked by ClpX AssociationClinical use of proteasome inhibitors in the treatment of multiple myelomaTrial Watch: Proteasomal inhibitors for anticancer therapyOrganizing principles of mammalian nonsense-mediated mRNA decayRegulation of proteasome activity in health and diseaseProteasome inhibitors act as bifunctional antagonists of human immunodeficiency virus type 1 latency and replication.Multiple sclerosis autoantigen myelin basic protein escapes control by ubiquitination during proteasomal degradationAssessing subunit dependency of the Plasmodium proteasome using small molecule inhibitors and active site probesAAA+ chaperones and acyldepsipeptides activate the ClpP protease via conformational control.Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Validation of the 2nd Generation Proteasome Inhibitor Oprozomib for Local Therapy of Pulmonary Fibrosis.Gates, Channels, and Switches: Elements of the Proteasome MachineTotal synthesis and absolute stereochemistry of the proteasome inhibitors cystargolides A and B.A strategy for dual inhibition of the proteasome and fatty acid synthase with belactosin C-orlistat hybrids.Discovery of Highly Selective Inhibitors of the Immunoproteasome Low Molecular Mass Polypeptide 2 (LMP2) Subunit.High-resolution cryo-EM proteasome structures in drug development.Inhibitors of the immunoproteasome: current status and future directionsProteasome inhibitor-adapted myeloma cells are largely independent from proteasome activity and show complex proteomic changes, in particular in redox and energy metabolismStructural basis for dynamic regulation of the human 26S proteasome.Blockade of the malignant phenotype by β-subunit selective noncovalent inhibition of immuno- and constitutive proteasomes.Structural biology of the proteasome.Proteasome inhibitors in acute leukemia.Synthesis and pharmacology of proteasome inhibitors.Proteasome inhibitors: possible novel therapeutic strategy for ischemia-reperfusion injury?Small-molecule control of intracellular protein levels through modulation of the ubiquitin proteasome systemPeptide-based proteasome inhibitors in anticancer drug design.Proteolysis mediated by cysteine cathepsins and legumain-recent advances and cell biological challenges.Proteasome inhibitors as experimental therapeutics of autoimmune diseases.Taspase1: a 'misunderstood' protease with translational cancer relevance.Emerging role of immunoproteasomes in pathophysiology.Proteasome inhibitors induce AMPK activation via CaMKKβ in human breast cancer cells.The cryo-EM structure of the Plasmodium falciparum 20S proteasome and its use in the fight against malaria.The role of the proteasome in AML.
P2860
Q27674685-A48FBCAF-AE7D-4624-AA3E-845AF7D5EF5EQ27687714-DB486051-B453-410B-B8E1-E751060CDA50Q27688108-6BE3DD97-9113-451C-B0C5-41AA40BFBB11Q27695633-CAC18D82-10D2-4E2C-B036-D2BE114DA048Q27697335-5711DEAC-A5C1-450E-B15A-04A22061B101Q27700842-DFAD44B0-63D9-4140-8C02-1C32C3C94BC0Q27701726-E73442DB-F96E-46FC-BD33-F3F3BBA0D8CCQ27702637-6FFFB371-4EFB-490E-8B79-C654506FCEB1Q28080999-542BAC74-32EC-4434-91CD-124C48FBBB37Q28082910-DEAD5E98-11B3-44A2-B31D-8143DF229C81Q28302705-BF3D5C62-9755-4A92-B7F4-0624C932AAF8Q28392708-96BDE20D-DC5E-4FD0-89C0-23A55D58336DQ33589167-A2D34B9B-FBE8-41C5-A0DB-6AC20D7D26D0Q33793002-B30889FB-22CE-42AB-B230-2E817602BC2BQ34061291-5F9D59D4-021D-4D46-AEF6-900E346A103DQ34463606-1AE7F7FF-DCBC-4553-8B57-0E169EED8A02Q34788381-7FF6E530-1404-4FED-A290-95890E856C2DQ35764713-D8526DA2-43A8-4992-B4EA-8681F48DCDD3Q35862786-F7184F86-FCC5-4522-A2C9-E1E983E625C5Q36239484-148D1F17-ADAE-4A59-B81E-73D84112DCABQ36290627-5484A7F4-459F-43F6-B778-C871544FCDA8Q36354644-E3A1EE2C-1B3A-4033-AD05-5B1633F04132Q36392578-380DC7E3-CD9A-4E13-9402-EE82EC7D2915Q37292307-67200553-450D-4384-AFB8-7751C77E0E95Q37396016-A3DE876A-7498-447E-AB3F-7946A5A7EEABQ37469477-E82B877A-C8A7-4DE4-A924-4FF9AD2A7347Q37705854-F2F777A6-DE2E-40CA-9355-5B40058571DFQ38081952-1B0F9A25-99D1-43EB-9FED-B8324D7FD53EQ38088003-A39C9541-3214-4F65-B790-AD478085A7DAQ38092777-5EC11767-5B5C-4862-96BF-D803E28C9EADQ38152513-15949C26-055E-485C-BE12-0DF6B522ADE3Q38181445-D255ED3A-06D0-4300-9D67-64215D2A4174Q38192572-F24B1607-DD8A-49A2-B817-A7E390B25BADQ38268345-FA918FE0-6CF5-48F1-9EC4-C1644F988CF3Q38427697-92FE29E5-6057-4E24-902E-9435007F389AQ38666356-0A65422A-9719-4E1F-AE79-E3E63BF2162EQ38837519-D329DEDD-23C1-439A-A294-2A72C1FA2B9DQ38847725-CE5A3F5E-F161-4931-91E3-959A9873BDD8Q38861425-72476C95-A2AA-42F6-8F19-88F78D64F566Q39027087-71FC0084-FCCB-4762-A7A3-BC3225651D14
P2860
Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Inhibitors for the immuno- and ...... re trends in drug development.
@en
type
label
Inhibitors for the immuno- and ...... re trends in drug development.
@en
prefLabel
Inhibitors for the immuno- and ...... re trends in drug development.
@en
P2860
P356
P1476
Inhibitors for the immuno- and ...... re trends in drug development.
@en
P2093
Eva Maria Huber
Michael Groll
P2860
P304
P356
10.1002/ANIE.201201616
P407
P577
2012-06-18T00:00:00Z